Liver Transplantation for Unresectable Neuroendocrine Tumor Liver Metastases
- 1k Downloads
Liver transplantation (LT) is performed in selected patients with neuroendocrine hepatic metastases. Survival benefit and the risk of tumor recurrence after LT, also exacerbated by immunosuppressive therapy, remain important clinical issues. Whether patients with particular types of neuroendocrine tumors (NET) benefit more than others is unclear.
Bibliographical searches were performed in PubMed for the terms “liver transplantation and neuroendocrine tumors,” “liver transplant and neuroendocrine tumors,” “liver transplantation and immunosuppressive therapy,” “tumor recurrence.”
Promising results have been reported for LT for NET metastases with 5-year survival of up to 90 % in patients with well-differentiated gastroenteropancreatic NETs, but only few patients are free of tumor 5 years after LT. Better outcomes have been reported for gastrointestinal tumors than for pancreatic NETs for both survival and risk or recurrence after LT. Selection criteria for LT are limited and include the 2007 Milan Criteria and the 2012 European Neuroendocrine Tumor Society guidelines, including: well-differentiated NET (Ki-67 <10 %), age <55 years, absence of extrahepatic disease, primary tumor removed before transplantation, stable disease for at least 6 months before LT, and <50 % liver involvement.
LT might be considered in carefully selected patients. The risk of tumor recurrence remains a significant clinical problem after LT, but data focused on immunosuppression issue are lacking, and there are no currently approved strategies for prevention of recurrence or follow-up protocols. Further studies are needed to define universally accepted inclusion criteria, reliable predictors of better outcome, and optimal timing for LT.
KeywordsLiver Transplantation Neuroendocrine Tumor Peptide Receptor Radionuclide Therapy Extrahepatic Disease Milan Criterion
Conflict of interest
The authors declare no conflict of interest.
- 3.Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, (eds). WHO classification of tumors of the digestive system. Lyon: International Agency for Research on Cancer (IRAC); 2010. p. 13–14.Google Scholar
- 4.Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–76.PubMedCrossRefGoogle Scholar
- 23.Sher L. Association between timing of resection of primary tumor in patients undergoing liver transplantation for metastatic neuroendocrine tumor and survival. Am J Transplant. 2009;12:88.Google Scholar
- 27.N’Guyen NT, Harring TR, Goss JA, O’Mahony C. Neuroendocrine liver metastases and orthotopic liver transplantation: the US experience. Int J Hepatol. 2011:742890.Google Scholar
- 28.Le Treut YP, Grégoire E, Klempnauer J, Belghiti J, Jouve E, Lerut J, et al; for ELITA. Liver transplantation for neuroendocrine tumors in Europe—results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg. 2013;257:807–15.Google Scholar
- 35.Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006;4:CD005161.Google Scholar
- 37.Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O’Beirne J, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. In press.Google Scholar